Stock Market News
Netscientific portfolio company nets positive report
Healthcare intellectual property commercialisation group Netscientific has today highlighted a positive report displaying the potential of Vortex Technology in cancer treatment.
Research into the technology, developed by Netscientific's portfolio company Vortex Biosciences, has yielded positive results according to the report published by Nature Scientific Reports.
Francois Martelet, chairman of Vortex Biosciences, said: "This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients."
The news comes just weeks after Netscientific hailed the progress of its portfolio companies Glycotest, ProAxsis, Wanda, PDS and the aforementioned Vortex Biosciences.
Glycotest, a liver diagnostics company based in the US, is planning to move forward with commercialization and secure its first sale while Wanda and PDS will hold financing events in 2018.
ProAxis expanded its contract with Diagenics and is targeting £1m in revenue in 2018 with the possibility of becoming free cash flow positive over the year.
"We are pleased to note that all of our core portfolio companies continue to advance their commercial operations and are well positioned for continued momentum as we move into 2018," Martelet said.
Research into the technology, developed by Netscientific's portfolio company Vortex Biosciences, has yielded positive results according to the report published by Nature Scientific Reports.
Francois Martelet, chairman of Vortex Biosciences, said: "This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients."
The news comes just weeks after Netscientific hailed the progress of its portfolio companies Glycotest, ProAxsis, Wanda, PDS and the aforementioned Vortex Biosciences.
Glycotest, a liver diagnostics company based in the US, is planning to move forward with commercialization and secure its first sale while Wanda and PDS will hold financing events in 2018.
ProAxis expanded its contract with Diagenics and is targeting £1m in revenue in 2018 with the possibility of becoming free cash flow positive over the year.
"We are pleased to note that all of our core portfolio companies continue to advance their commercial operations and are well positioned for continued momentum as we move into 2018," Martelet said.
Related share prices |
---|
NetScientific (NSCI) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price